Transforming medical innovations currently at the prototype stage into reality to better combat the threat of Emerging Infectious Diseases & AMR

IDCluster’s purpose is to accelerate the market launch of innovative products for patients or to accelerate the use of solutions for public authorities in the two areas of MIE and AMR, by transforming accelerated R&D projects from their prototype stage into reality.

Accelerate prototype-stage innovations

Requirements for an R&D project in the EID or AMR fields to be eligible for acceleration by IDCluster, including France 2030 funding:

Being a member of IDCluster (the project leader and its partners within a consortium).

Meet the eligibility and selection criteria adopted by the Health Innovation Agency and IDCluster.

Accept the application procedure set out in IDCluster’s internal regulations.

Accept the terms of the innovative project acceleration agreement and the principle of jointly adopting an acceleration plan of the same duration as the France 2030 aid agreement concluded with BpiFrance.

IDCluster’s missions:

Identify R&D projects that can be accelerated among promising projects pre-accelerated by IDCluster or following sourcing

Identify innovative technology platforms that can support the accelerated development of new products

Support the operational teams of accelerated projects by facilitating access to resources mobilized by IDCluster

Stimulate interaction between IDCluster-accelerated project leaders and stakeholders in production, from process development to the production of clinical trial batches and then commercial batches

These various actions to stimulate innovation will be carried out in collaboration with IDCluster’s founders and partners.

IDCluster activities

ID360 Platform

Stimulate innovation

Accelerate innovation

Facilitate acceleration